Agreement Details - BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for its PyroGlu-Aβ antibody program, including BAN1503 and BAN2803 [1] - The agreement includes a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments, with tiered low double-digit royalties on global product sales [1][2] - Bristol Myers Squibb will be solely responsible for the development and commercialization of BAN1503 and BAN2803 worldwide, while BioArctic retains an option to co-commercialize in the Nordic region [2] Technology and Program Overview - The PyroGlu-Aβ antibody program targets a specific truncated, pyroglutamate-modified form of amyloid-beta, which is highly prone to aggregation and contributes to Alzheimer's disease symptoms [3] - BAN2803 incorporates BioArctic's BrainTransporter technology, which utilizes the transferrin receptor (TfR) to optimize brain delivery of biotherapeutics across the blood-brain barrier [4] - The BrainTransporter technology has potential applications in various therapy areas for delivering biologic molecules, offering future partnering opportunities for BioArctic [5][8] Strategic Implications - The agreement with Bristol Myers Squibb marks the first license agreement involving BioArctic's BrainTransporter technology, specifically for PyroGlu-Aβ antibody treatments [5] - BioArctic retains all other rights to the BrainTransporter platform, which is being applied to several in-house drug projects and could be part of future collaborations [5][8] - The partnership aligns with Bristol Myers Squibb's strategy to strengthen and diversify its neuroscience portfolio, leveraging innovative approaches like the BrainTransporter technology [5] Company Background - BioArctic is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS [9] - The company co-developed Leqembi (lecanemab), the first drug proven to slow Alzheimer's progression, in partnership with Eisai [9] - BioArctic's research portfolio includes multiple projects utilizing its proprietary BrainTransporter technology to enhance treatment efficacy by actively transporting antibodies across the blood-brain barrier [9]

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS") China on December 16th. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, and Mr. Wen Yizhong, the head of the Innovative Medicines Division at BMS China and General Manager for BMS Hong Kong.This strategic al ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of BMY, PFE, A ...

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recen ...

Bristol-Myers Squibb Company (NYSE:BMY) Citi’s 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us. My name is Geoff Meacham. I'm the Senior Biopharma Analyst and we have Mary ...

Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.But solid companies don't always make for the perfect investments, especially when investors have outsized expectat ...

The sell-offs of these stocks were driven by issues that were never going to last.Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story. For your truly long-term holdings, you'll want companies that are not only leading names with staying power, but that also operate in resilient markets -- a rarer set of criteria.Of course, if such a stock is on sale at the time you're ready to take the plunge, so much the ...

POLAND - 2024/11/22: In this photo illustration, the Bristol-Myers Squibb company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ. However, ...

When I last wrote about the pharmaceuticals company Bristol-Myers Squibb Company (NYSE: BMY ) in August, I had given it a Sell rating for the short term. This was based on the likelihood of a price drop on the releaseManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Gia ...

Generating thousands of dollars of recurring income can be a great way to make you less reliant on employment income or retirement benefits. If you have savings that you can afford to invest in stocks, there are multiple high-yielding dividend investments to consider right now. While many investors have been focusing on growth stocks and hype surrounding artificial intelligence, dividend stocks have been on the back burner of late, which could make now an advantageous time to invest in them.Three dividend s ...